GlassScriptPhysician profile
Denise Hedgepeth
NPI 1558769729
$4,717.78
in general payments reported to CMS, 2019-2025
27 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,014 · 2022: $1,443 · 2023: $613 · 2024: $293 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.79 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,152.64 | 2021-2025 | |
| Janssen Biotech, INC. | $696.57 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $471.05 | 2021-2025 | |
| Genzyme Corporation | $431.32 | 2021-2025 | |
| Leo Pharma INC. | $262.50 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $218.18 | 2021-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $185.32 | 2021-2023 | Ilumya |
| Pfizer INC. | $182.02 | 2021-2023 | |
| Ucb, INC. | $180.99 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $180.61 | 2021-2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $122.30 | 2021 | |
| Allergan, INC. | $97.20 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $95.67 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $71.94 | 2023-2025 | Dupixent |
| Journey Medical Corporation | $67.03 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $48.03 | 2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.38 | 2023 | Jublia, Arazlo |
| Kyowa Kirin, INC. | $28.23 | 2024 | Poteligeo |
| Almirall LLC | $28.08 | 2023 | Klisyri |
| Amgen INC. | $25.73 | 2022 | |
| Merz North America, INC. | $25.23 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $22.78 | 2022 | |
| Biocon Biologics INC | $21.82 | 2025 | Yesintek |
| Organon LLC | $19.78 | 2025 | Vtama |
| Biofrontera INC. | $19.14 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $15.28 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.96 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Hedgepeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.